P1.11-02 Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C

KRAS mutation accountsthe one of the most frequent alterations in non-small cell lung cancer (NSCLC).For 40 years, the KRAS mutations had been considered undruggable until theadvent of inhibitors targeting KRASG12C, but it just coveredabout 13% of NSCLC. The strategy of approximately 20% of NSCLC harboring other KRASmutation types including KRASG12F, KRASG12D,KRASQ61H, KRASG12V and KRASG12Ais still considered elusive.